Communication between cells is vital for maintenance of immune homeostasis and is also required for rapid and effective immune responses. Nowhere is this balance of activity more important than at mucosal surfaces such as the respiratory tract, where resident cells must ignore potentially antigenic inhaled material while responding swiftly to clear viruses and bacteria. In this issue, Bourdonnay et al. describe a novel form of intercellular communication that helps to explain how alveolar macrophages and epithelial cells maintain pulmonary homeostasis.
Diffuse large B cell lymphoma (DLBCL) is a heterogeneous B cell malignancy that can be stratified into three molecular subtypes using gene expression profiling: activated B cell-like DLBCL (ABC-DLBCL), germinal center B cell-like (GCB-DLBCL), or mediastinal B cell-like. In this issue, Schmid et al. report that aberrant methylation results in loss of DUSP4 expression in most (75%) DLBCL cases, suggesting that DUSP4 functions as a novel tumor suppressor.
The dual-specificity phosphatases (DUSPs) are a family of 25 phosphatases that can dephosphorylate both tyrosine and serine/threonine residues. A primary substrate of the DUSPs are the MAP kinases, which are inhibited by dephosphorylation of a critical motif in the kinase domain.
In this study, the authors first screened for potential DLBCL tumor suppressors that could be epigenetically silenced by DNA methylation. They used genome-wide DNA methylation analyses coupled with gene expression profiling after pharmacological DNA demethylation and identified DUSP4 as one of eight genes impairing cell survival when ectopically expressed in DLBCL lines. Of the MAP kinase targets of DUSP4, they focused on JNK1/2, because these kinases, unlike ERK1/2 and p38, were dephosphorylated in both ABC-DLBL and GCB-DLBCL. Further experiments showed that DUSP4 acts on nuclear JNK and that a small molecule JNK inhibitor targets the survival of selected DLBCL lines. This finding was validated in xenograft experiments, showing tumor reduction in animals receiving the JNK inhibitor. Interestingly, an additive effect was observed
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The Journal of Experimental Medicine in ABC-DLBCL lines after coinhibition with a JNK inhibitor and ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, suggesting that JNK and BTK are synthetic lethal targets downstream of the BCR. Lastly, the absence of DUSP4 negatively correlated with patient survival in all subtypes of DLBCL.
This study illustrates the power of systematic epigenetic approaches in understanding dysregulated gene expression. DUSP4 is a relatively understudied target in cancer, whereas its substrates, the MAP kinases, are well-known regulators of cell fate. Additional investigations will be required to determine the relevance of the DUSP4/JNK1/2 axis in the stratification and treatment of other lymphoma types that also lack DUSP4. Moreover, the physiologic targets of JNK that promote lymphoma cell viability remain to be determined. The combinatorial effects of BTK and JNK inhibitors are intriguing and worthy of further study. In particular, it will be important to attribute the relative efficacy and synergy of these inhibitors to particular receptors/pathways versus prevalent off-target effects. Notch signaling induces and supports T cell lineage differentiation in the intrathymic microenvironment. Although the antigen-independent specification of the B cell lineage is known to occur in the bone marrow, it is not clear whether engagement of Notch1 receptors on hematopoietic progenitors is required to initiate T cell lineage development.
In this issue, Yu et al. assessed the influence of bone marrow stromal cells on the generation of thymic-seeding progenitors (TSPs). The authors took advantage of several in vivo mouse models to tackle this question and showed that osteoblasts appear to influence the generation of TSPs through expression of DLL4, thus providing an initial Notch signal within the bone marrow and initiating T cell lineage specification. When osteoblasts were destroyed, or their ability to express DLL4 was compromised, lower numbers of putative TSPs (defined as Lineage
 cells) were detected in the bone marrow. This also led to a reduced number of early thymocyte progenitors (ETPs, typically defined as CD4
 cells) and other subsets of developing thymocytes, including reduced numbers of mature CD4 + and CD8 + T cells. These results strongly point to a prethymic defect in the generation of several lymphocyte progenitor subsets. However it is curious, and somewhat unexpected, to note a decreased number of intrathymic precursor cells, such as later CD4  CD8  subsets; due to their strong proliferative capacity, these cells typically compensate for defects associated with decreased progenitor cell numbers. A cursory analysis of genes expressed by immature thymic epithelial cells (TECs), or subsets of TECs, points to the possibility that the osteocalcin gene promoter (used to drive the loss of osteoblasts or loss of DLL4 expression) may also be expressed by these cells. Additionally, it is well established that reduced Notch signaling during T cell development can lead to severe blocks in differentiation and cell survival of early thymocyte subsets. So, although the authors conclude that the "data demonstrate the role of Notch ligands 
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